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Abstract
Background: We investigated causal effect of completed growth, measured by adult
height, on coronary heart disease (CHD), stroke and cardiovascular traits, using instru-
mental variable (IV) Mendelian randomization meta-analysis.
Methods: We developed an allele score based on 69 single nucleotide polymorphisms
(SNPs) associated with adult height, identified by the IBCCardioChip, and used it for IV
analysis against cardiovascular risk factors and events in 21 studies and 60028 partici-
pants. IV analysis on CHD was supplemented by summary data from 180 height-SNPs
from the GIANT consortium and their corresponding CHD estimates derived from
CARDIoGRAMplusC4D.
Results: IV estimates from IBCCardioChip and GIANT-CARDIoGRAMplusC4D showed that
a 6.5-cm increase in height reduced the odds of CHD by 10% [odds ratios 0.90; 95% confi-
dence intervals (CIs): 0.78 to 1.03 and 0.85 to 0.95, respectively],which agrees with the esti-
mate from the Emerging Risk Factors Collaboration (hazard ratio 0.93; 95% CI: 0.91 to 0.94).
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IV analysis revealed no association with stroke (odds ratio 0.97; 95% CI: 0.79 to 1.19). IV
analysis showed that a 6.5-cm increase in height resulted in lower levels of body mass
index (P< 0.001), triglycerides (P<0.001), non high-density (non-HDL) cholesterol
(P< 0.001), C-reactive protein (P¼ 0.042), and systolic blood pressure (P¼ 0.064) and higher
levels of forced expiratory volume in 1 s and forced vital capacity (P< 0.001 for both).
Conclusions: Taller individuals have a lower risk of CHD with potential explanations
being that taller people have a better lung function and lower levels of body mass index,
cholesterol and blood pressure.
Introduction
Observational studies have shown associations of adult
height used as a measure of completed growth, with major
non-communicable diseases.1,2,3,4 Studying over 1 million
participants, the Emerging Risk Factors Collaboration
(ERFC) found a 6% decrease in risk of dying from coron-
ary heart disease (CHD) and stroke per 6.5 cm increase in
adult height.4 Controversy remains about the explanations
for these associations. Some authors suggest adult height is
only a proxy of circumstances affecting growth in infancy
and childhood,2,5 whereas others argue for confounding by
behavioural, psychosocial and biological factors. Finally,
reverse causation could arise from ‘shrinkage’ in early
stages of disease.1,5,6
Given that genetic variants are unlikely to be affected
by the wide range of confounders that usually bias multi-
variable analyses and cannot be influenced by reverse caus-
ality, we employed a multiple instruments Mendelian
randomization approach7,8,9 to investigate the causal effect
of completed growth, measured by adult height, with CHD
and stroke and examine several cardiovascular traits to
gain insight about potential mechanisms.
Methods
We included individual participant data from 60 028 par-
ticipants of European ancestry from 21 prospective studies
(for details see Table S1, available as Supplementary data
at IJE online) with recorded standing adult height and at
least one of the outcomes (CHD or stroke). All participat-
ing studies obtained informed consent for DNA analysis
and received ethical approval.
Two multiple instruments were created. The first incorp-
orates 69 loci identified in a gene-centric meta-analysis of
height with the Institute for Translational Medicine and
Therapeutics (ITMAT) Broad Institute CARe consortium
(IBC) CardioChip array10,11 (a chip designed to assess SNPs
across relevant loci for a range of cardiovascular disease
(CVD) syndromes), and was applied in 21 prospective stud-
ies (60 028 participants) with access to individual participant
data. The second was based on summary data from 180 stat-
istically independent height-associated SNPs from the
Genetic Investigation of ANthropometric Traits (GIANT)
Consortium12 and their corresponding summary CHD esti-
mates derived from the Coronary Artery Disease Genome-
wide Replication and Meta-analysis (CARDIoGRAM) plus
the Coronary Artery Disease (C4D) Genetics Consorium,
collectively known as CARDIoGRAMplusC4D,13 down-
loaded from [http://www.CARDIOGRAMPLUSC4D.org].
The GIANT Consortium12 was a meta-genome-wide associ-
ation study (GWAs) including 183 727 individuals, that
identified 180 independent loci associated with adult
height, explaining 10% of the phenotypic variation. The
CARDIoGRAMplusC4D Consortium13 identified SNPs
Key Messages
• Observational studies show associations of adult height with risk of coronary heart disease (CHD) and stroke; how-
ever, these associations could arise from confounding or reverse causality
• To investigate the causal effect, we conducted a multi-locus Mendelian randomization study incorporating data from
180 height-related SNPs using both individual participant data from prospective cohorts and summary data from
large genetics consortia
• A 6.5-cm increase in adult height (instrumented by 180 SNPs) causally reduced the odds of CHD by 10%, with poten-
tial mechanisms including blood pressure, body mass index and non-HDL cholesterol; the effect of adult height on
stroke was less clear.
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associating with CHD in 63 746 CAD cases and 130 681
controls.
Genotyping was conducted with the IBC Cardiochip
array in 16 studies,14 and with Metabochip15 in the five re-
maining studies (Table S2, available as Supplementary
data at IJE online).We selected 69 SNPs, representing 69
different loci, independently associated with adult height
at array-wide significance (P< 2.4106) in gene-centric
meta-analysis of height from 114 223 individuals and 47
studies genotyped with the IBC Cardiochip array (includ-
ing 16 studies also analysed here) to construct the allele
score.10 In the five studies with Metabochip genotyping,
we used imputed SNPs in linkage disequilibrium (R2> 0.8)
with those from IBC Cardiochip.16 SNPs were coded as 0,
1 and 2 indicating the number of height-raising alleles.
A per-allele positive effect weighted by the summary beta
coefficients from the meta-analysis was summed for each
risk allele to construct an allele score.10 In a sensitivity ana-
lysis, allele scores were constructed without weighting, to
address potential overfitting given that the studies included
here contributed to the meta-analysis that provided the
weights.
The primary outcome was prevalent or incident (fatal
and non-fatal) CHD. The secondary outcome was preva-
lent or incident (fatal and non-fatal) stroke including
haemorrhagic or ischaemic events. Validated events were
preferred over non-validated, self-reported events. Details
for outcome definitions in each study are provided in
Table S3, available as Supplementary data at IJE online.
To gain insight into the mechanisms that may explain
the association of height with CHD and stroke, we used
available information from individual studies on estab-
lished or promising risk factors for CHD and stroke [sex,
age, blood pressure, body mass index, smoking, type 2
diabetes, high-density lipoprotein (HDL) cholesterol,
non-HDL cholesterol, triglycerides, fasting glucose,
C-reactive protein; for details see Table S4, available as
Supplementary data at IJE online] and on lung function
[forced expiratory volume in 1 s (FEV1), forced vital cap-
acity (FVC)] given the established association with adult
height.2
Statistical analysis
The same analytical script was used by all studies. For each
of the SNPs (69 SNPs for studies using IBC CardioChip
and 35 for studies using Metabochip; Table S5, available
as Supplementary data at IJE online), we calculated
frequencies of the height-increasing allele and P-values for
Hardy–Weinberg equilibrium. In each study, we fitted re-
gression models to estimate the association between adult
height and the allele score, with the allele score treated as a
continuous trait or divided into deciles. We estimated the
proportion of variance (R2) of height explained by the al-
lele score and the corresponding standard error by boot-
strapping. We used inverse-variance weighted fixed-effects
meta-analysis to pool estimates across studies.17
We used linear or logistic regression models to examine
the genetic association of the allele score with clinical
events, cardiovascular traits and confounders (smoking) in
individual studies. Owing to skewed distributions, trigly-
cerides and C-reactive protein were analysed on the natural
logarithmic scale. For comparability across cardiovascular
traits, the original values were divided by the standard
deviation. Fixed-effect meta-analysis was used to estimate
pooled associations across studies.
For the instrumental variable (IV) analysis, we used
the logistic control function estimator to estimate study-
specific odds ratios (ORs) between height and clinical
events.18,19 This involved a two-stage process: we first con-
ducted within each study a linear regression analysis with
adult height as the dependent variable and the allele score
as the independent variable. The residuals from the first
step were then incorporated into a logistic regression
model of the binary trait on the predicted adult height
from the first stage. We specified heteroskedasticity robust
standard errors in the second stage to incorporate the un-
certainty in the estimated residuals from the first stage.
Results were expressed as odds ratios (ORs) per 6.5 cm
height with corresponding 95% confidence intervals (CIs)
to make them comparable to observational estimates from
the ERFC.4 For continuous traits, we used two-stage least
squares analysis using the allele score as the IV for adult
height. We also fitted IV models including the following
cardiovascular risk factors as covariables: systolic blood
pressure, body mass index, lipids [triglycerides, non-HDL
cholesterol], lung function [FEV1, FVC] and C-reactive
protein. The reason we selected these traits is that they
were identified (by our genetic instrument) as potential
downstream biological consequences of height. This ap-
proach required that studies had measured the traits of
interest; studies without this information were excluded.
We pooled study-specific instrumental variable esti-
mates using fixed-effects meta-analysis.20 We calculated I2
statistics to quantify heterogeneity between studies and
derived P-values from Cochran’s Q test.21 All P-values are
two-sided.
In a separate analysis, we used published data from
both the GIANT and CARDIoGRAMplusC4D consortia
to conduct a multiple instrument Mendelian randomiza-
tion meta-analysis of adult height on CHD using summary
level data. For the 180 GWAs height loci reported in
GIANT, we extracted the rs number, beta coefficient, ef-
fect allele and P-value. We approximated the Z statistic by
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taking the inverse cumulative standard normal distribution
of the P-value and divided the beta coefficient by the Z
statistic to obtain the standard error. We identified the cor-
responding SNPs and summary estimates for CHD in the
CARDIoGRAMplusC4D Consortium and arranged SNPs
so that the estimates for height and CHD corresponded to
the same reference allele (Table S6, available as
Supplementary data at IJE online). Using the summary es-
timates for height and CHD, we synthesized instrumental
variable estimates for each SNP by dividing the SNP-CHD
association by the SNP-height association and using the
delta method to approximate the standard error.22 This
generated an instrumental variable estimate for each of the
180 individual SNPs, which we pooled using fixed-effects
meta-analysis to yield a summary effect of height on
CHD.20
Results
A total of 21 studies (60 028 participants) with data on
IBC CardioChip array were included (Tables S2 and S4)
with a median age at baseline of 61 years (range 26 to 74
years), and 51% were women (range 0% to 100%). The
median height was 169 cm (range 156 to 175 cm). In total,
there were10 848 CHD and 4 878 stroke cases.
Adult height increased by 0.79 cm (95% CI: 0.75 cm,
0.84 cm) per one-unit increase in allele score derived from
the IBC CardioChip array with low heterogeneity across
studies (I2¼ 29%, P¼ 0.108) (Figure 1), and explained
1.4% (95% CI: 1.2%, 1.5%) of the variance in adult
height. The allele score showed no association with smok-
ing (20 studies with 57 075 participants including 32 665
smokers, OR 0.97; 95% CI: 0.87, 1.07).
An IV analysis, using the allele score derived from IBC
CardioChip array, that included 19 studies with 10 848
prevalent or incident CHD cases, found that for each 6.5-
cm increase in adult height the pooled OR of CHD was
0.90 (95% CI: 0.78, 1.03). The corresponding IV estimate
derived from summary data from 180 independent SNPs
from the GIANT and CARDIoGRAMplusC4D Consortia
(including up to 183 727 individuals with height and
63 746 CHD cases) yielded an OR of CHD of 0.90 (95%
CI: 0.85, 0.95) for the same difference in adult height.
These IV estimates were in agreement with the observa-
tional estimate reported by the ERFC (hazard ratio 0.93,
95% CI: 0.91, 0.94, Figure 2).4
We analysed 4 878 cases of stroke in 43 790 partici-
pants in 17 studies (Figure 2) with data on IBC
CardioChip array. The ERFC observed an OR of 0.93
(95% CI: 0.91, 0.96) per 6.5 cm difference in adult height.
Our pooled IV estimate for the same height difference
showed a not very dissimilar point estimate, though with
wide confidence intervals (OR 0.97, 95% CI: 0.79, 1.19).
Study-specific causal estimates for the effect of height
on risk of CHD and stroke in the studies for which we had
access to participant data are presented in Figures S1 and
S2 (available as Supplementary data at IJE online). These
did not show a relationship between study precision and
Figure 1.Meta-analysis pooled estimates for the association between deciles of the allele score and adult height. Presented are pooled differences in
mean adult height with corresponding 95% confidence intervals as compared with the 5th decile, derived from fixed-effect meta-analysis. N, numbers
analysed in each decile.
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the IV estimate, which would arise from weak instrument bias
and thus bias the overall meta-analysis of IV estimates. SNP-spe-
cific instrumental variable estimates derived from summary-level
data (GIANT and CARDIoGRAMplusC4) are presented in
Figure S3 and a cross-hair plot showing the relationship of
height and risk of CHD across the SNPs is presented in Figure
S4 (available as Supplementary data at IJE online). These show
significant heterogeneity, suggesting that the causal effect identi-
fied by the allele score is a composite of multiple causal path-
ways which identify different magnitudes of causal effect.
Instrumental variable analyses of height derived from
IBC CardioChip array on cardiovascular traits, showed
that an increase of 6.5 cm in adult height had the strongest
association with lung function, with a difference of 0.26
standard deviation (SD) units of FEV1 (95% CI: 0.15,
0.36) and of 0.30 SD units of FVC (95% CI: 0.20, 0.41)
(Table 1). An increase of 6.5 cm in height associated with
lower levels of body mass index (0.10 SD units, 95% CI:
-0.15, 0.05), triglycerides (0.10 SD, 0.16, 0.05),
non-HDL cholesterol (0.12 SD, 0.17, 0.06),
Figure 2. Meta-analysis pooled causal effects for a 6.5-cm increase in adult height on the risk of cardiovascular disease. Odds ratios and correspond-
ing 95% confidence intervals (CI) are estimated from fixed-effect meta-analysis of instrumental variable (IV) estimates from individual studies. Hazard
ratios are taken from estimates published by the Emerging Risk Factors Collaboration (ERFC).4 Effect estimates are per 6.5 cm increase in adult height.
An estimate below 1 indicates that increasing adult height decreases the risk of cardiovascular events.
Table 1. Meta-analysis pooled estimates derived from instrumental variable analysis for a 6.5-cm increase in adult height on
cardiovascular traits. Traits are sorted according to the magnitude of the association observed with adult height
Characteristic No studies/
participants
Difference per SD in
trait for a 6.5-cm
increase in height
(95% CI)
P value,
Z-test
Heterogeneity,
I2 (Cochran’s Q test P-value)
FVC 6/11129 0.30 (0.20, 0.41) <0.001 0% (0.774)
FEV1 6/11131 0.26 (0.15, 0.36) <0.001 0% (0.735)
Non-HDL cholesterol 17/41477 –0.12 (–0.17, –0.06) <0.001 32% (0.102)
Triglyceridesa 17/42117 –0.10 (–0.16, –0.05) <0.001 0% (0.513)
Body mass index 20/54099 –0.10 (–0.15, –0.05) <0.001 30% (0.100)
C-reactive proteina 15/35538 –0.07 (–0.13, –0.00) 0.042 0% (0.761)
Systolic blood pressure 19/52345 –0.05 (0.10, 0.00) 0.064 0% (0.467)
Fasting glucose 18/40451 –0.04 (–0.10, 0.01) 0.127 13% (0.302)
HDL cholesterol 18/43030 0.02 (–0.03, 0.08) 0.432 33% (0.089)
Results from instrumental variable analyses are derived from 2-stage least-squares regression and pooled using fixed-effects meta-analysis.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HDL, high-density lipoprotein.
aEffects of triglycerides and C-reactive protein are estimated after log-transformation. A negative difference indicates that levels of traits decrease with an in-
crease in adult height.
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C-reactive protein (0.07 SD, 0.13, 0.00) and a trend
to lower levels in systolic blood pressure (0.05 SD,
0.10, 0.00). We did not find evidence for an association
between adult height and fasting glucose (0.04 SD,
0.10, 0.01) or type 2 diabetes (19 studies, 60 171 partici-
pants,7340 cases, OR per 6.5 cm height 0.99, 95% CI:
0.85, 1.15).
In an exploratory analysis using a sub-sample of pro-
spective studies with clinical events and cardiovascular
traits, we conducted a multivariate IV analysis that
included height and the traits that showed an association
with the gene score for height (blood pressure, BMI, lipids,
lung function and CRP). These analyses suggested a dimin-
ution of the IV estimate between adult height and CHD
(Figure S5, available as Supplementary data at IJE online).
The null effect for stroke remained unchanged after adjust-
ment for these traits.
Results for IV analysis derived from the IBC
CardioChip array with CHD, stroke and cardiovascular
traits using an unweighted allele score were similar to
those externally weighted (Table S7, available as
Supplementary data at IJE online).
Discussion
In order to investigate the causal effect of completed
growth, measured by adult height, on cardiovascular
events and traits, we used multiple genetic instruments
(derived from IBC CardioChip array, and GIANT-
CARDIoGRAMplusC4D consortia) associated with adult
height representing completed growth, and through IV
analysis showed that genetically taller individuals had a
lower risk of CHD as well as differences in several cardio-
vascular (CV) traits that may explain the cardio-protective
effect. The IV estimate indicates a 10% risk reduction in
CHD for every 6.5 cm increase in standing height. This is
in agreement with the observational estimate reported by
the ERFC.4 Although we did not find evidence for a causal
effect between adult height and risk of stroke, the IV esti-
mate was imprecise, meaning we cannot exclude a causal
effect.
Our analysis showed that genetically taller individuals
had lower levels of adiposity (body mass index), lipid frac-
tions (non-HDL cholesterol and triglycerides) and better
lung function. Our results suggest that these physiological
variables may contribute to explain the association of adult
height (and completed growth) on CHD. Additional biolo-
gical mechanisms, which we were not able to explore,
might also explain the observed effects on CHD. For ex-
ample, shorter individuals have smaller vessel calibre,23
which becomes more easily occluded leading to increased
arterial occlusive events,24 and have a higher risk of more
advanced coronary atherosclerosis.25 Shorter individuals
also have faster heart rate and increased augmentation of
the primary systolic pulse, indicating greater ventricular
systolic work.26
According to the principles of Mendelian randomiza-
tion, we would expect the genetic variants to be evenly dis-
tributed with respect to potential confounding factors.
However in this particular case, with respect to exposures
acting in utero, a potential confounding factor described as
a “dynastic effect” may lead to an imbalance whereby
adults carrying more height raising alleles may have experi-
enced greater on average maternal height (due to genomic
sharing between mothers and offsping). This greater mater-
nal height could affect the in utero environment experi-
enced by the offspring, which could possibly influence
their long-term health.27 However, these early environ-
mental determinants of adult height are unlikely to entirely
explain the association of adult height with CHD, derived
from our IV analysis. However, it does not mean that early
growth, a key period when these genes act, is not an im-
portant mechanism.28 Since genotype is invariant, our re-
sults also suggest that the reverse causation phenomenon
of ‘shrinkage’ due to illness does not explain our effect of
adult height on CHD. Furthermore, we did not observe an
association between the allele score and smoking, which is
a potential confounder.
Mendelian randomization studies using IV methods
have been used for causal inference for a broad range of
environmental exposures and diseases.29,30,31 However,
the validity of the IV results depends on whether or not the
IV assumptions (strength of the genetic instrument, mini-
mization of confounding and specificity) hold in each
specific case. First, we used multiple genetic instruments
that substantially increase the proportion of the variance in
height explained by the instrument (1.4% by IBC
CardioChip array and 10% by GIANT consortium), which
together with a large number of clinical events (in particu-
lar for CHD) lead us to counteract weak instrument bias.
Of note, there was no evidence that smaller studies were
more affected by weak instrument bias. Second, our gen-
etic instrument for height was not associated with smok-
ing, showing the ability to reduce confounding due to
Mendel’s second law. Third, the use of multiple instru-
ments increased the specificity of our genetic instrument
(compared with any single instrument);18 this is especially
important for non-protein traits that are not encoded for
by a specific gene. Thus, although the significant hetero-
geneity among individual SNP IV estimates suggests pos-
sible non-specificity for some SNPs, taken together we
expect the multiple instruments to have greater specificity,
reflected in the similar IV estimates from the 69 and 180
SNP instruments. As a consequence of the strength and
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specificity of our genetic instrument, we were also able to
dissect the downstream biological consequence of the
intermediate trait of interest (i.e. differences in blood pres-
sure, lung function and lipid traits as consequence of differ-
ences in adult height), known as vertical pleiotropy32,33
and its presence does not violate the IV assumptions. We
weighted the IBC CardioChip allele score by the summary
beta coefficients from the meta-analysis,10 which included
all of the studies in this analysis and, therefore, there is a
risk of overfitting in the IV estimates. However, when we
compared our results with IV results obtained from un-
weighted scores, we found very similar results,9,34,35 sug-
gesting that the magnitude of potential overfitting to be
unlikely to invalidate our findings. Fourth, our findings are
in alignment with a very recent Mendelian randomization
study of height and risk of coronary artery disease;36 we
additionally considered the effect of height on risk of
stroke, and our access to participant data from the UCLEB
consortium allowed us to explore potential mediators of
the relationship between adult height and CHD.
An interesting finding from our IV analysis on cardio-
vascular traits was that taller people tend to have lower
body mass index. Previous studies have shown that
whereas adult height is directly associated with most body
girths, it is inversely associated with waist girth.37 A link
between short stature and adiposity may emerge through
associations between poor growth in early life and altered
metabolism,38 which may allow partial reduction of the
height deficit while also favouring insulin resistance and
central fat accumulation.
The main strength of our study is use of the Mendelian
randomization approach incorporating data from two very
large consortia consisting of studies with validated cardio-
vascular endpoints, and two different multiple-genetic
instruments. Our approach of using multiple SNPs in com-
bination for Mendelian randomization has been used for
causal inference for a broad range of environmental expos-
ures and diseases (including BMI39 and lipids17) and use
of an allele score in this regard yields reliable causal
estimates.40
One limitation of our study was that we were unable to
explore additional biological mechanisms, which might
also explain the causal effects of height on CHD. Second,
we rescaled the IV effect for comparability with the pub-
lished ERFC results, which is only valid when assuming a
linear association between the height and the IV effect.
Third, the absence of association of our genetic instrument
with risk of stroke should be interpreted with caution:
additional Mendelian randomization studies using
multiple instruments in larger sample sizes (such as
METASTROKE) are needed to clarify the effect of adult
height on stroke. Interesting next steps would include
expanding this approach to cancer, as well as exploring the
potential effect modification that adverse conditions dur-
ing pregnancy or in early childhood may have on the asso-
ciations of health outcomes with genetic instruments for
completed growth.41
Summary
Our multiple instruments Mendelian randomization
approach provided evidence that people with a genetic
predisposition to achieve a higher completed growth,
measured by adult height, have a reduced risk of CHD,
and with potential mechanisms including better lung func-
tion and lower levels of body mass index, non-HDL choles-
terol, triglycerides and blood pressure.
Supplementary Data
Supplementary data are available at IJE online.
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